LWB Stock Overview
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Mesoblast Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.94 |
| 52 Week High | AU$1.07 |
| 52 Week Low | AU$0.13 |
| Beta | 2.34 |
| 11 Month Change | 9.88% |
| 3 Month Change | 81.73% |
| 1 Year Change | 314.47% |
| 33 Year Change | -11.93% |
| 5 Year Change | -14.86% |
| Change since IPO | 162.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| LWB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 5.6% | -1.9% | -0.2% |
| 1Y | 314.5% | -17.2% | 7.8% |
Return vs Industry: LWB exceeded the German Biotechs industry which returned -17.7% over the past year.
Return vs Market: LWB exceeded the German Market which returned 7.9% over the past year.
Price Volatility
| LWB volatility | |
|---|---|
| LWB Average Weekly Movement | 13.3% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LWB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: LWB's weekly volatility has decreased from 20% to 13% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 73 | Silviu Itescu | www.mesoblast.com |
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn’s disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease.
Mesoblast Limited Fundamentals Summary
| LWB fundamental statistics | |
|---|---|
| Market cap | €1.13b |
| Earnings (TTM) | -€83.01m |
| Revenue (TTM) | €5.57m |
202.7x
P/S Ratio-13.6x
P/E RatioIs LWB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LWB income statement (TTM) | |
|---|---|
| Revenue | US$5.90m |
| Cost of Revenue | US$41.07m |
| Gross Profit | -US$35.17m |
| Other Expenses | US$52.79m |
| Earnings | -US$87.96m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.077 |
| Gross Margin | -595.87% |
| Net Profit Margin | -1,490.27% |
| Debt/Equity Ratio | 23.8% |
How did LWB perform over the long term?
See historical performance and comparison